The information provided by this gene panel testing allows for personalized treatment decisions based on the genomic characteristics of the tumor. This approach improves treatment outcomes by selecting therapies that are more likely to be effective and minimizing the use of treatments that are unlikely to provide benefit.

Patients with dHRR cancers, characterized by HRD-associated mutations, often exhibit increased sensitivity to specific treatments. By identifying these mutations through this gene panel test, oncologists can predict the patient’s potential response to these targeted therapies.

This gene panel testing helps identify patients with dHRR cancers, making them potential candidates for PARP inhibitor therapy. This targeted approach improves treatment outcomes by directing patients toward therapies that are more likely to be effective.

This gene panel testing is recommended by clinical guidelines for screening patients who will benefit from certain types of treatment. These guidelines are evidence-based recommendations developed by field experts designed to optimize patient care.